Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Sheila Mariano

Internal Medicine Jonesboro, LA Medical Doctor

NPI 1104896919 CMS profile 480409

121 Watts St, Jonesboro, LA 71251

Open in the dashboard

General payments

$1,875

99 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Sheila Mariano of Jonesboro, LA is reported in the CMS Open Payments database as having received $1,875 across 99 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 78th percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $357 16
2024 General $285 16
2023 General $330 16
2022 General $373 20
2021 General $84 5
2020 General $116 7
2019 General $329 19

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Sheila Mariano
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Sheila Mariano were reported at $357. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Sheila Mariano Internal Medicine median Middle half National median
2019 $329 $159 $48–$570 $163
2020 $116 $119 $33–$402 $114
2021 $84 $135 $37–$521 $132
2022 $373 $141 $42–$496 $149
2023 $330 $149 $45–$519 $160
2024 $285 $154 $47–$537 $164
2025 $357 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AstraZeneca Pharmaceuticals LP $250 14 payments
  2. Lilly USA, LLC $240 13 payments
  3. Amgen Inc. $214 11 payments
  4. Novo Nordisk Inc $177 11 payments
  5. Merck Sharp & Dohme Corporation $172 11 payments
  6. AbbVie, Inc. $110 5 payments
  7. Abbott Laboratories $108 5 payments
  8. Boehringer Ingelheim Pharmaceuticals, Inc. $96 6 payments
  9. Bayer HealthCare Pharmaceuticals Inc. $87 4 payments
  10. Alpha Cognition USA, Inc. $87 1 payment
  11. Other $336 18 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $1,875 99 payments
Products named General payments · program years 2019–2025
  1. RYBELSUS $161 10 payments
  2. Ozempic $161 10 payments
  3. MOUNJARO $148 8 payments
  4. Repatha $147 8 payments
  5. FARXIGA $104 6 payments
  6. STEGLATRO $97 6 payments
  7. Prolia $96 5 payments
  8. BREZTRI $90 5 payments
  9. Kerendia $87 4 payments
  10. Zunveyl $87 1 payment
  11. Other $1,596 81 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 157 drugs

Part D claims

9,846

Median for Internal Medicine: 777

Drug cost

$796,354

Median for Internal Medicine: $73,373

Branded share of claims

21.5%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ozempic Semaglutide Brand 79 $96,408
Farxiga Dapagliflozin Propanediol Brand 115 $84,481
Mounjaro Tirzepatide Brand 57 $83,057
Jardiance Empagliflozin Brand 71 $72,693
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 74 $54,508
Eliquis Apixaban Brand 47 $42,569
Januvia Sitagliptin Phosphate Brand 42 $32,625
Synjardy Xr Empagliflozin/Metformin Hcl Brand 42 $28,588
Glyxambi Empagliflozin/Linagliptin Brand 18 $26,092
Prolia Denosumab Brand 13 $21,611

The 10 drugs with the highest cost, of 157 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Payments and prescribing

First 5 of 9 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
MOUNJARO
  • Lilly USA, LLC $57
$57 57 —
BREZTRI
  • AstraZeneca Pharmaceuticals LP $47
$47 — —
RYBELSUS
  • Novo Nordisk Inc $45
$45 — —
Ozempic
  • Novo Nordisk Inc $45
$45 79 —
AIRSUPRA
  • AstraZeneca Pharmaceuticals LP $20
$20 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 9 in the dashboard with a free account

Records

99 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in Louisiana

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record